Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
GRC-54276 by Ichnos Glenmark Innovation for Breast Cancer: Likelihood of Approval
GRC-54276 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Breast Cancer. According to GlobalData,...
GRC-54276 by Ichnos Glenmark Innovation for Ovarian Cancer: Likelihood of Approval
GRC-54276 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Ovarian Cancer. According to GlobalData,...
GRC-54276 by Ichnos Glenmark Innovation for Cervical Cancer: Likelihood of Approval
GRC-54276 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Cervical Cancer. According to GlobalData,...
GRC-54276 by Ichnos Glenmark Innovation for Colon Cancer: Likelihood of Approval
GRC-54276 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Colon Cancer. According to GlobalData,...
ISB-1442 by Ichnos Glenmark Innovation for Relapsed Multiple Myeloma: Likelihood of Approval
ISB-1442 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Relapsed Multiple Myeloma. According to...
ISB-1442 by Ichnos Glenmark Innovation for Refractory Multiple Myeloma: Likelihood of Approval
ISB-1442 is under clinical development by Ichnos Glenmark Innovation and currently in Phase II for Refractory Multiple Myeloma. According to...
ISB-2001 by Ichnos Glenmark Innovation for Multiple Myeloma (Kahler Disease): Likelihood of Approval
ISB-2001 is under clinical development by Ichnos Glenmark Innovation and currently in Phase I for Multiple Myeloma (Kahler Disease). According...
ISB-2001 by Ichnos Glenmark Innovation for Relapsed Multiple Myeloma: Likelihood of Approval
ISB-2001 is under clinical development by Ichnos Glenmark Innovation and currently in Phase I for Relapsed Multiple Myeloma. According to...
ISB-2001 by Ichnos Glenmark Innovation for Refractory Multiple Myeloma: Likelihood of Approval
ISB-2001 is under clinical development by Ichnos Glenmark Innovation and currently in Phase I for Refractory Multiple Myeloma. According to...